Results of Renal Transplantation in Patients With Schistosoma Infection

Barrou, B.; Bitker, Marc Olivier; Boyer, Christian; Sylla, C; Chatelain, C

doi:10.1016/s0022-5347(01)64932-2

Cited by 15 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bout et al [20,21] reported a curative and protective effect of cyclosporin against primary and secondary S. mansoni in mice and rats. However, this observation was not supported by others, as schistosomal re‐infection was diagnosed in patients receiving cyclosporin [10,11,13].…”

Section: Schistosomiasis Of the Recipientsmentioning

confidence: 65%

“…There was no correlation between the schistosomal antibody titre and incidence or frequency of graft rejection [13]. Gazzinelli et al [14] showed that the titres of anti‐schistosomal antibodies decline and stabilize as the infection progresses.…”

Section: Schistosomiasis Of the Recipientsmentioning

confidence: 99%

“…Schistosomal re‐infection is diagnosed in about a quarter of renal transplant recipients [10,11,13]; patients are then hospitalized and undergo:…”

Section: Schistosomiasis Of the Recipientsmentioning

confidence: 99%

See 2 more Smart Citations

Renal transplantation: the impact of schistosomiasis

Shokeir

2001

BJU International

View full text Add to dashboard Cite

Section: Schistosomiasis Of the Recipientsmentioning

confidence: 65%

Section: Schistosomiasis Of the Recipientsmentioning

confidence: 99%

See 1 more Smart Citation

Renal transplantation: the impact of schistosomiasis

Shokeir

2001

BJU International

View full text Add to dashboard Cite

“…For Strongyloides, 55% of our panel recommended an intermediate delay (C; 2) (Table ) . The panel noted that the approach to Schistosoma infection depends on the clinical scenario.…”

Section: Resultsmentioning

confidence: 99%

Infections among pediatric transplant candidates: An approach to decision‐making

L’Huillier

Green

Danziger‐Isakov

et al. 2019

Pediatric Transplantation

View full text Add to dashboard Cite

Introduction The presence of infections in the immediate pretransplant period poses challenges in decision‐making. Delaying transplantation because of these infections may be required, but is associated with a risk to the potential recipient. The aim of this project was to develop a structured framework based on expert opinion to guide decision‐making regarding the safety of transplantation for candidates with infection immediately before transplant, and to show how this framework can be applied to clinical scenarios. Methods Categories were created as follows: Category A: no delay; Category B: brief delay (≤1 week); Category C: intermediate delay (>1 week); and Category D: more prolonged or indefinite delay. A survey containing 59 clinical scenarios was sent to members of the IPTA ID CARE committee. Answers were reviewed, and the level of agreement was characterized as follows: Level 1: ≥75% agreement; Level 2:51%‐74% agreement; and Level 3: ≤50% agreement. 95% CIs were calculated for the mean overall agreement across 59 scenarios. Results Among the panel, the agreement level ranged from 33% to 92% with the mean overall agreement across the 59 scenarios being 61%. For 7/59 scenarios, the lower bound of 95% CI was greater than 50%, indicating a difference at the 5% level of significance between the observed proportion and the chance level of 0.5. Summary The document provides expert opinion regarding the need to delay transplantation in the setting of different infections. The most important points in the decision to proceed to SOT included the urgency of transplantation and the severity of infection.

show abstract

“…However, there was no significant difference in graft rejection, recipient survival rate, and the incidence of malignancy between these two groups. The risk of recurrence because of reactivation of chronically hosted pathogens post renal transplantation appears to be low in patients who received antischistosomal chemotherapy at pretransplant evaluation 3 . In patients with recurrent urological complications and a compatible travel history, urinary schistosomiasis should be considered and biopsy may be indicated to exclude this uncommon aetiology.…”

mentioning

confidence: 99%